Composition and Methods for Sensitizing Androgen Receptor Positive Breast Cancers to Radiation

Questions?

Contact Innovation Manager

Jason Ospina, PhD

What is it? What does it do?

Our methods are intended for the identification of markers for the response of cancers to chemotherapy and radiation. The goal is to inform future clinical trials of personalized therapies used in combination with current standard of care drugs. Our data will serve as an important resource that can be used to develop therapeutic hypotheses and to accelerate discovery of drugs given concurrently with chemotherapy or radiation matched to patients by their cancer genotype. An example pertains to our discovery that the receptor that regulates androgen response in breast cancer (androgen receptor or AR) makes tumors that express this receptor resist radiation.
Integration of high-throughput radiation survival profiling with large-scale cancer genomic data suggests AR expression is associated with therapeutic resistance in breast cancer. Our analysis nominates anti-androgen therapies, which are commercially available and currently in clinical use in prostate and breast cancer, as therapeutic sensitizers in select AR positive breast cancer. Further investigation has the potential to yield an additional genotype-directed therapy that could impact up to 20% of patients with breast cancer.
 

Why is it better?

Our methods enable the identification of markers for the response of cancers to chemotherapy and radiation. The goal is to inform future clinical trials of personalized therapies used in combination with current standard of care drugs.
 

What is its current status?

Tested in xenograft animal model


IP Status

Images/Videos

Attachments

News

Publications

Other Technologies by Inventor

Get in Touch With Us